- Text-only version of this website
- Skip navigation
- Home page
- What's new
- Contact Webmaster
- Website policies
- Disability services
The Brusko lab received a 5-yr, $1,250,000 NIH (R01) grant from the National Diabetes and Digestive and Kidney Diseases (NIDDK) entitled “The CD226 and TIGIT co-stimulatory axis in type 1 diabetes”. The […]
TIGIT and CD226 provide important phenotypic markers for assessing the role of Tregs in health and disease
Immune therapy for treating type 1 diabetes challenges existing paradigms
During a live webinar, physicians and medical researchers from around the globe learned that a $3.3M grant has been awarded to nPOD collaborators at UM and UF.
Our laboratory aims to harness the power regulatory T-cells to control unwanted immune responses to deliver a cure for type 1 diabetes.
From undergraduate students to post-doctoral fellows – every set of hands is important.